{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:06:20Z","timestamp":1767902780342,"version":"3.49.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>After expiry of the patent of originator anti-tumor necrosis factor drug infliximab (Remicade), CT-P13 was in 2013 the first infliximab biosimilar to be approved by the European Medicine Agency (EMA) for the same indications as the reference drug, including paediatric inflammatory bowel disease (IBD). The approval was based on extrapolation, after extensive in-vitro studies and clinical experience in patients with ankylosing spondylitis and rheumatoid arthritis. The extrapolation of CT-P13 to IBD and to paediatric patients raised concerns among paediatric IBD specialists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Now, almost 4 years later, we can conclude that those concerns have been resolved. There are a growing number of postmarketing studies and real-life data, so far mostly in adults and some in children with IBD. These studies show reassuring comparable efficacy, safety and immunogenicity between CT-P13 and the reference Infliximab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In Europe, biosimilars are increasingly regularly prescribed drugs in paediatric IBD. Due to their lower cost, treatment expenses have gone down considerably (up to 30% or more in some countries) and patient access has improved. However, additional well designed studies to investigate long term follow-up of biosimilars in children are still needed. In addition, clinical studies addressing pharmacokinetics, pharmacodynamics and optimal use of infliximab (originator as well as biosimilar) are still desirable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000529","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T14:43:43Z","timestamp":1499438623000},"page":"560-565","source":"Crossref","is-referenced-by-count":6,"title":["The use of biosimilars in paediatric inflammatory bowel disease"],"prefix":"10.1097","volume":"29","author":[{"given":"Maria Myrthe Elisabeth","family":"Jongsma","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus Medical Center\/Sophia Children's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Vulto","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus Medical Center\/Sophia Children's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MCG.0000000000000696","article-title":"Biological therapy in pediatric inflammatory bowel disease: a systematic review","volume":"51","author":"Corica","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"R2-20230918","article-title":"Biosimilars in the EU","author":"Agency","year":"2017","journal-title":"Edited by"},{"key":"R3-20230918","article-title":"Assessment report Flixabi","author":"Agency","year":"2016","journal-title":"Edited by"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: the science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"},{"key":"R5-20230918","article-title":"Assessment report Inflectra","author":"Agency","year":"2013","journal-title":"Edited by"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1185\/03007995.2016.1145579","article-title":"Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents","volume":"32","author":"Vezer","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/clpt.2011.343","article-title":"The state of the art in the development of biosimilars","volume":"91","author":"McCamish","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4161\/mabs.32221","article-title":"Physicochemical characterization of Remsima","volume":"6","author":"Jung","year":"2014","journal-title":"MAbs"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.semarthrit.2015.04.002","article-title":"Clinical trial development for biosimilars","volume":"44","author":"Alten","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R13-20230918","article-title":"The impact of Biosimilar competition in Europe","author":"XXX","year":"2017","journal-title":"Edited by"},{"key":"R14-20230918","article-title":"Huge discount on biosimilar infliximab in Norway Edited by: Generics and Biosimilars Initiative","author":"International","year":"2015"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/bmjgast-2016-000123","article-title":"Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial","volume":"3","author":"Cozijnsen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2014.02.007","article-title":"Biosimilars: in support of extrapolation of indications","volume":"8","author":"Ebbers","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: facts and fears of extrapolation","volume":"14","author":"Ben-Horin","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1542\/peds.2012-2412","article-title":"IOM Review of FDA: approved biologics labeled or studied for pediatric use","volume":"131","author":"Field","year":"2013","journal-title":"Pediatrics"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-immunol-032414-112151","article-title":"Mechanisms of pediatric inflammatory bowel disease","volume":"34","author":"Peloquin","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.crohns.2014.06.007","article-title":"Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization","volume":"8","author":"Danese","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjw090","article-title":"Changes in biosimilar knowledge among European Crohn's Colitis Organization [ECCO] Members: an updated survey","volume":"10","author":"Danese","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.13990","article-title":"Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of antitumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases","volume":"45","author":"Komaki","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MPG.0000000000000903","article-title":"Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN Paediatric IBD Porto Group","volume":"61","author":"de Ridder","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R31-20230918","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000001643","article-title":"Induction therapy with biosimilar infliximab in children with Crohn's disease","author":"Sieczkowska-Golub","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","article-title":"Interchangeability of biosimilars: a European perspective","volume":"31","author":"Kurki","year":"2017","journal-title":"BioDrugs"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14712598.2012.711308","article-title":"The safety of switching between therapeutic proteins","volume":"12","author":"Ebbers","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"R37-20230918","first-page":"27","article-title":"Biosimilar medical products: licensing, pharmacovigilance and interchangeability","volume":"37","author":"Grozdanova","year":"2016","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201710000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:04:09Z","timestamp":1695002649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201710000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000529","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}